Category
Peptides and peptide analogs targeting incretin receptors (GLP-1, GIP, glucagon) to regulate appetite, blood sugar, and body weight. This rapidly evolving category includes FDA-approved therapies and next-generation multi-receptor agonists.
3 peptides in this category
Also known as: Ozempic, Wegovy, Rybelsus
A long-acting GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management, achieving ~15-17% body weight reduction in clinical trials.
Also known as: LY3437943, Reta
An investigational triple hormone receptor agonist (GIP/GLP-1/glucagon) that achieved up to 24.2% body weight reduction in Phase 2 trials, representing the next frontier in metabolic peptide therapy.
Also known as: Mounjaro, Zepbound, LY3298176
A first-in-class dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes and weight management, achieving up to ~22.5% body weight reduction.